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Abstract: The first confirmed case of Zika virus infection in the Americas was reported in Northeast
Brazil in May 2015, although phylogenetic studies indicate virus introduction as early as 2013.
Zika rapidly spread across Brazil and to more than 50 other countries and territories on the American
continent. The Aedes aegypti mosquito is thought to be the principal vector responsible for the
widespread transmission of the virus. However, sexual transmission has also been reported.
The explosively emerging epidemic has had diverse impacts on population health, coinciding with
cases of Guillain–Barré Syndrome and an unexpected epidemic of newborns with microcephaly and
other neurological impairments. This led to Brazil declaring a national public health emergency in
November 2015, followed by a similar decision by the World Health Organization three months later.
While dengue virus serotypes took several decades to spread across Brazil, the Zika virus epidemic
diffused within months, extending beyond the area of permanent dengue transmission, which is
bound by a climatic barrier in the south and low population density areas in the north. This rapid
spread was probably due to a combination of factors, including a massive susceptible population,
climatic conditions conducive for the mosquito vector, alternative non-vector transmission, and
a highly mobile population. The epidemic has since subsided, but many unanswered questions
remain. In this article, we provide an overview of the discovery of Zika virus in Brazil, including
its emergence and spread, epidemiological surveillance, vector and non-vector transmission routes,
clinical complications, and socio-economic impacts. We discuss gaps in the knowledge and the
challenges ahead to anticipate, prevent, and control emerging and re-emerging epidemics of
arboviruses in Brazil and worldwide.
Keywords: Zika virus; microcephaly; Congenital Zika Syndrome; epidemiology; surveillance; vector
control; socio-economic impact
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1. Zika Virus Emergence and Spread in Brazil
Zika virus (ZIKV) infection is an acute exanthematous disease transmitted by the same vectors as
some of the most significant arthropod-borne viral diseases in the world, including dengue, chikungunya,
and yellow fever [1]. The virus circulated silently in Africa and Asia for over half a century with few
records describing the clinical presentations of ZIKV infection, which are similar to other arboviral
infections. Symptoms include mild fever, rash, arthritis, headache, conjunctivitis, and edema [2]. There
is one ZIKV serotype with two ZIKV lineages (African and Asian) and three ZIKV genotypes (West
African, East African, and Asian). In 2007, the first ZIKV outbreak was reported in Yap island, Micronesia,
followed by epidemics in several Pacific Islands, including French Polynesia, between 2013 and 2014 [3].
An Asian ZIKV genotype is thought to have arrived in Brazil as early as 2013, sharing a common ancestor
with the ZIKV strain that circulated during the French Polynesian epidemic [4]. The first reports of an
unknown exanthematic disease outbreak in Brazil, later identified as ZIKV infection, were issued in
December 2014. In May 2015, the spread of ZIKV among the local population was laboratory confirmed,
first in the states of Pernambuco (PE), Rio Grande do Norte (RN), and Bahia (BA) in the Northeast region,
then in other states of the Central-West and Southeast regions [5,6]. Figure 1 summarises the spread of
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Figure 1. Spatial diffusion of Zika virus (ZI ) in Brazil from 2014 to 2016 according to case reports
and epidemiologic data produced by the Federal Ministry of Health and state secretaries of health [7].
The current permanent dengue transmission area is shown in grey [8].
By 2016, ZIKV had spread t most stat s, xcept some remote areas in the Amazon region
and the south rnmost portion of the co ntry, here the climate is not favourable fo he vector.
While the ZIKV epidemic spread to a vast area in just a few months, the four dengue virus (DENV)
serotypes (DENV1-4), also transmitted by Aedes mosquito vectors, took several decades, spreading
through coastal and tropical zones between 1980 and 2010 and more recently towards inland areas
and higher altitudes. ZIKV transmission also spread beyond the boundaries of permanent DENV
transmission (Figure 1), which is limited by a climatic barrier in the south and low population density
areas in the north [8,9]. The unknown rate of asymptomatic cases makes it difficult to ascertain
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true population-level exposure, but a recent serosurvey conducted in Salvador in Northeast Brazil
suggested a peak seroprevalence of 63% by 2016 [10]. Overall, the number of reported ZIKV cases in
Brazil has decreased from 205,578 cases in 2016 to 13,353 in 2017 (up to epidemiological week 25) [11],
with population immunity thought to be the main cause of the decline [12]. However, continued
transmission of the four DENV serotypes in Brazil and the Americas over many decades suggests that
ZIKV will continue to circulate within the human transmission cycle for the foreseeable future [13].
In this article, we provide an overview of the current knowledge of the ZIKV epidemic from the
Brazilian perspective, including the discovery of severe complications related to the virus, vector and
non-vector ZIKV transmission routes, clinical features, and the social and economic impact of the
disease. We discuss gaps in the knowledge and the challenges ahead in anticipating, preventing, and
controlling emerging and re-emerging epidemics of ZIKV and other arboviruses in the future.
2. A Public Health Emergency
2.1. Building the Evidence
ZIKV was considered a benign disease until October 2015, when a sharp increase in the number of
neonates born with microcephaly, a rare condition associated with incomplete brain development, was
observed in maternity services in Northeast Brazil [14]. Specialists from Recife raised the hypothesis
of an association between ZIKV infection in pregnancy and microcephaly. The Brazilian Ministry of
Health then established compulsory notification of microcephaly. On 12 November 2015, the Ministry
of Health declared a national public health emergency [15]. On 1 February 2016, the World Health
Organization (WHO) declared Zika a public health emergency of international concern [16]. At the
time, there was no direct scientific evidence of a causal relationship between ZIKV infection during
pregnancy and congenital brain defects in fetuses or newborns, although the spatial diffusion of the
microcephaly epidemic followed the ZIKV spread paths from an epicentre in the Northeast region
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Figure 2. Spatial diffusion of microcephaly in Brazil, June 2015 to March 2016. Data obtained from
the public health events registry (RESP) information system, provided to the authors by the Brazilian
Ministry of Health.
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Some characteristics of the Brazilian epidemic were helpful in establishing the link between ZIKV
infection and microcephaly and other congenital malformations of the central nervous system (CNS)
early in the ZIKV epidemic. Firstly, the huge population affected by the infection. In the French
Polynesian epidemic, approximately 32,000 presented with the disease among 268,000 inhabitants [17],
while in Brazil, more than 200,000 cases were notified by the end of 2016 (see Figure 3) [18]. Secondly,
the high reach of the unified public health system, including hospitals in which more than 80% of
babies are delivered. The public health obstetricians and neonatologists within this community, dealing
with hundreds of childbirths per month, were the first to suspect something was amiss. Thirdly, the
close network of practitioners and researchers working within the public health system, including
doctors, midwives, epidemiologists, and other academics exchanging information and reporting new
findings in a timely fashion. From November 2015, reports of suspected microcephaly cases increased
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Figure 4. Notified microcephaly cases  for  the main regions of Brazil  (North, Northeast, Southeast, 
South, and Central‐West) per epidemiological week from January 2015 to April 2016. Data obtained 
from the RESP information system. 
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Figure 4. Notified microcephaly cases for the main regions of Brazil (North, Northeast, Southeast,
South, and Central-West) per epidemiological week from January 2015 to April 2016. Data obtained
from the RESP information system.
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The first case definition of ZIKV infection adopted by the Brazilian Ministry of Health was
presented in a protocol for the surveillance and response of ZIKV-related microcephaly [19].
The suspected case definition for pregnant women was broader, including any acute exanthematic
disease, unless another cause was identified. The overlap in the space-time epidemiological distribution
of Zika, dengue, and chikungunya, and their non-specific clinical manifestations, was challenging for
providing accurate diagnosis and reporting. Zika case confirmation included laboratory diagnostics
through reverse transcription polymerase chain reaction (RT-PCR). However, this test is not available
in most Brazilian states. Further, diagnosis can be problematic due to the limited window of time
that viral particles persist in the bloodstream, a large proportion of asymptomatic infections, and
the antibody cross-reactivity between ZIKV and other flaviviruses, especially the four dengue virus
serotypes, DENV1-4 [13].
The suspected link between ZIKV infection and microcephaly was a highly debated topic in
academia and the media. Controversies included the sensitivity and specificity of the cranial measures
to define microcephaly [20,21] and alternative causes of the microcephaly epidemic, including the use of
Pyriproxifen in drinking-water [22] and a rubella vaccine used in pregnant women. In December 2015,
the 49th annual meeting report of the Latin American Collaborative Study of Congenital Malformations
concluded that there was not enough evidence to prove the occurrence of a microcephaly epidemic in
Brazil, or the causal relationship between ZIKV infection and the congenital syndrome [23]. In fact, the
need to be ‘absolutely’ sure about this public health emergency could have impaired the subsequent
investigation. The function of public health surveillance systems is to provide actionable information,
allowing decision-makers to respond to anomalies in the system as quickly as possible. The scientific
controversy resulted in a delayed response, especially for the women and girls suffering the worst
impacts of the Zika epidemic [24].
2.2. Epidemiological Surveillance and Health Information Systems
Several data sources have proved useful for the epidemiological investigation of ZIKV in Brazil.
These include the national notifiable information system (SINAN), as well as information systems on
mortality (SIM), newborns (SINASC), and public hospitals discharge (SIH), scaled to the municipality
level (5570 municipalities distributed across 27 states).
In November 2015, a new public health events registry (RESP) was created and implemented
during the emergency response for notification of cases of microcephaly, other congenital anomalies,
and fetal loss, based on the monitoring of pregnant women and their newborn babies [25]. An updated
protocol for ZIKV-related microcephaly and other CNS disorders related to congenital infections was
published in March 2016 to describe the epidemiological patterns [26]. However, Zika itself did not
become a notifiable disease on SINAN until 17 February 2016 [27]. By the end of 2016, approximately
17% of women with ZIKV infection were pregnant (96,494 cases reported in women of a childbearing
age) [28]. However, important information, such as education level and race/skin colour, were missing
in most of the notification forms, making it difficult to later evaluate risk by socio-economic situation.
Recent studies have explored the use of these health information systems to detect changes
in disease patterns that could be attributable to ZIKV. Barcellos et al. [29] detected a four-fold
increase in congenital malformations of the nervous system in the SIH in the Northeast region
of Brazil from mid 2014 to early 2016. De Oliveira et al. [30] used both the specific RESP and
the SINASC, linked together using individual information, such as full name, available only for
ethically approved projects. The authors found large variations in ZIKV-related microcephaly incidence
between different regions in 2015–2016, varying from almost 5 to 50 per 10,000 live births. These two
studies highlight the importance of timely access to secondary data and careful use of record linkage
processes [31]. While these analyses present a promising approach, other experiments should be
considered for disease surveillance, even when the disease is not yet of public health importance [32].
For example, public-health-integrated surveillance systems, instead of disease-based ones, have been
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Aedes aegypti is considered to be the main vector of ZIKV in urban and suburban areas together
with Aedes albopictus [34–36]. Ae. aegypti and Ae. albopictus share similar larval habitats, co-occuring in
both natural and artificial containers. Both vectors are invasive species in many regions of the world,
including Brazil [37,38], and are closely associated with the human peridomestic environment [39–41].
Ae. aegypti is a diurnal mosquito, highly anthropophilic and endophilic, that consumes blood multiple
times per gonothophic cycle, a behaviour that reinforces its potential as an arbovirus vector. In contrast,
Ae. albopictus shows an eclectic feeding behaviour, preferentially feeding and resting in the peridomicile,
and is more common in vegetated, rural, and urban forest transition habitats, especially where
sympatric with Ae. aegypti [37,38,40,42]. Ae. aegypti inhabits most of Latin America east of the Andes
and north of Argentina, reaching the southeast of the United States of America (USA). In Brazil, the
most infested country on the continent, the vector is present in all states and in 4834 of the 5570
municipalities. Ae. albopictus distribution extends even further, almost reaching the Great Lakes in
the USA, due to its tolerance of milder and lower temperatures [43]. ZIKV has been detected in
field-caught Ae. aegypti mosquito specimens [44–46], such as those from the densely urbanised slums
of Rio de Janeiro [46].
The ability of different vector species to transmit ZIKV and other arboviruses is sensitive to a
combination of factors, including vector population, virus strain, and environmental factors, such
as ambient temperature and diurnal temperature range. Both venereal and vertical transmission
in mosquitoes is possible, providing a potential mechanism for the virus to survive in adverse
environmental conditions [47–49]. A recent study evaluated the vector competence of Ae. aegypti
and Ae. albopictus populations from across the Americas for the ZIKV Asian genotype. High infection
but lower disseminated infection and transmission rates was observed for both species, suggesting
low competence to transmit ZIKV [35]. In contrast, another study showed that orally exposed
Ae. aegypti mosquitoes were highly competent, with transmission rates of up to 73% for ZIKV,
21% for chikungunya virus (CHIKV), and 12% of mosquitoes transmitting both viruses in one
bite [50]. Other studies have also shown simultaneous transmission of alphaviruses and flaviviruses in
Ae. albopictus and Ae. aegypti [51–53].
Several laboratory experiments have reported significant differences in ZIKV susceptibility
between mosquito species, including Ae. aegypti, Ae. albopictus, and Culex quinquefasciatus [35,54–56].
A study conducted in Brazil detected ZIKV in the midgut, salivary glands, and saliva of
laboratory-reared Cx. quinquefasciatus females [56]. Another study in China showed the ability of
Cx. quinquefasciatus to become infected and transmit ZIKV under laboratory conditions [57]. In contrast,
field populations of Cx. quinquefasciatus collected in four different sites in Rio de Janeiro, Brazil, were
not able to transmit ZIKV under experimental conditions. After an experimental oral infection, the
tested populations failed to present dissemination or transmission three weeks post-exposure [58].
Other experimental studies found no species of the genus Culex capable of transmitting ZIKV [59–61].
These studies show differences in susceptibility of Culex vectors to ZIKV, indicating a complex
interaction between the virus and different mosquito species. As discussed elsewhere [62,63], these
experiments should be replicated, preferably at the local level, in places that are already endemic or
receptive to ZIKV transmission.
ZIKV originated and continues to circulate in a sylvatic transmission cycle between nonhuman
primate hosts and arboreal mosquitoes in Africa and Asia [64,65]. In tropical Africa, ZIKV strains
have been isolated from different mosquito species, including Aedes furcifer, Aedes taylori, and
Aedes luteocephalus [66]. A survey in Senegal detected the presence of Zika virus RNA by RT-PCR
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in ten species from the genus Aedes, as well as from Mansonia uniformis, Anopheles coustani, and
Culex perfuscus [64]. A modelling study revealed a high probability of the establishment of sylvatic
ZIKV in the Americas with a focus on Brazil, which has multiple species of primates and mosquitoes
potentially capable of ZIKV transmission [65]. ZIKV has now been detected in neotropical primates
in Brazil [67]. In other parts of the world, ZIKV antibodies have been found in wild and domestic
animals, including sheep, cows, rodents, and bats [68]. More research is needed to better understand
the potential for nonhuman primates and other animals to be ZIKV reservoirs and the risk they pose
for ZIKV transmission to humans.
3.2. Non-Vector-Borne Transmission
ZIKV can also be transmitted via sexual contact and blood transfusions. Studies demonstrated the
presence and persistence of ZIKV in the male and female genitourinary tract by testing sperm, urine,
and vaginal secretions from infected patients over extended periods of time [69–72]. However, the
maximum duration of infectivity of semen and female genital fluids and the impact of ZIKV infection
in sexual transmission in areas with or without vector-borne transmission is not known. ZIKV has
also been detected in breast milk [73,74], although the transmission of ZIKV through breast milk has
not yet been reported [75]. The transmission of ZIKV by blood transfusion was reported in Brazil in
2016 [76]. However, as with sexual transmission, transfusion-transmitted infection is difficult to prove
and measure in mosquito-exposed endemic areas [71].
4. Clinical Manifestations of ZIKV
Besides the mild febrile exanthematic clinical manifestation of ZIKV infection, itching is an
important symptom during the acute period. Two main severe neurological ZIKV-related complications
have been identified: Guillan–Barré Syndrome (GBS), a rare condition in which a person’s immune
system attacks the peripheral nerves, also described in the 2013 French Polynesia Zika outbreak [77],
and microcephaly, the more severe end of a spectrum of birth defects [78], which is sometimes referred
to as Congenital Zika Syndrome (CZS) [79].
The detection of ZIKV in the amniotic fluid of pregnant women with fetuses with microcephaly
and in fetal brain tissue were the first pieces of evidence that supported the hypothesised link between
ZIKV infection during pregnancy and severe fetal/newborn sequelae [80]. Definitive epidemiological
evidence was initially derived from two studies in Brazil: a cohort of pregnant women in Rio de Janeiro,
which detected congenital abnormalities in 12 fetuses from 42 ZIKV-positive women (29%), but
none in 16 ZIKV-negative women [81]; and a case-control study conducted in Recife, in which 32
microcephaly cases as well as 64 control neonates without microcephaly were enrolled. Forty-one
percent of microcephaly cases and none of the controls had laboratory evidence for ZIKV infection [82].
Microcephaly and other birth defects in ZIKV-infected mothers had not been recognised previously in
other parts of the world. Possible reasons include herd immunity, a lack of diagnostics and surveillance
in epidemic areas, and the possibility of contemporary ZIKV strains acquiring adaptive mutations
to become more virulent to the human fetal brain [83]. The evidence for causality between ZIKV
infection and birth defects has been extensively reviewed [84,85]. The risk of vertical transmission
exists throughout pregnancy for both symptomatic and asymptomatic mothers [86], although the exact
risk of microcephaly and other birth defects following ZIKV infection is unknown. Medium- and
long-term follow-up with careful standardised evaluations are needed to determine overall outcomes
in the exposed infants, including rates of developmental delay, hearing and visual impairments, seizure
and feeding disorders, as well as later outcomes, such as learning disabilities.
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5. Control and Prevention Strategies
5.1. Vector Control
Currently, there are no viable ZIKV-specific vaccines or therapies available. Therefore, vector
control is the primary method for the control and prevention of mosquito-borne diseases, such as
ZIKV [87,88]. Several control strategies have been implemented in urban areas of Brazil, but there is
no evidence that any recent vector-control interventions, such as mechanical and biological control or
the use of larvicide and insecticides, have had any significant effect on DENV transmission [89,90].
The House Index—a household larval survey—is typically used to guide vector control efforts, but
this approach has been found to be ineffective and expensive [89]. Both Aedes vectors are widely
distributed and numerous in most small and large cities [38,46]. Rapid human population growth,
uncontrolled urbanization, including slum settlements with inadequate infrastructure and piped
water, and insecticide resistance, have made it very difficult to reduce Ae. aegypti populations to safe
levels [90,91].
In Brazil, several new approaches are being implemented to change paradigms in Ae. aegypti
control. In Recife, a massive trap intervention was implemented for two years with population
suppression of about 90% [92]. Sterile [93], transgenic mosquitoes [94] and mosquitoes bearing
Wolbachia [95,96] are being released under field-controlled conditions to better evaluate their impact
on local vector populations and arbovirus transmission. There are promising results regarding
transgenic mosquitoes, with sustained release reducing field populations of Ae. aegypti by 81–95% [97].
Mosquito-disseminated Pyriproxyfen is another novel control strategy being used in Brazil, with
promising results regarding the reduction of field populations of Ae. aegypti and the predicted number
of dengue cases [98,99].
5.2. Mathematical Modelling to Guide Interventions
Mathematical and computational modelling approaches, integrating demographic, human
mobility, climate, socio-economic, and mosquito density data, have been developed to understand
the spread and magnitude of ZIKV epidemics in the Americas [100], estimate the international spread
of the virus from Brazil [101], and project the near-term risk of ZIKV infection and the associated
congenital syndrome [102]. However, the interpretation of model results is limited by many factors,
including the unknown rate of asymptomatic infection, herd immunity, and inconsistencies in case
reporting [103]. Some ZIKV predictions have been extrapolated from empirical models of DENV [104].
A recent study used a two-vector basic reproduction number model to quantify the impact of climate
variability on ZIKV and other arbovirus transmission [105]. The authors found that temperature
conditions at the beginning of 2015, related to a strong El Niño event, were exceptionally conducive
for mosquito-transmitted diseases and could have been successfully predicted at least 1 month in
advance for several high-risk ZIKV zones, including the epicentre of the epidemic in Northeast Brazil.
Previous studies have used real-time seasonal climate forecasts to produce dengue early warnings
for Brazil [106,107]. A combination of forecast climate and seroprevalence survey data could improve
predictions of the timing and magnitude of outbreaks of multiple arboviruses, including ZIKV [108].
An important question for the modelling community is why the epidemic in the Americas seems to
have run its course. Herd immunity is thought to have played a major role [12]. However, the extent
to which other factors, such as vector control, modified human behavior, and reporting practices, may
have contributed to the apparent decline in ZIKV cases is not well-understood [109]. Well-formulated
predictive models are needed to help policy-makers anticipate when and where the next epidemic of
ZIKV or another emerging infectious disease is likely to hit, to plan vaccination campaigns, and target
innovative vector control technologies to the most at risk areas [110].
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5.3. Birth Control
Although data is limited, guidance is needed for couples who are exposed to ZIKV and planning
pregnancy. Advice from the Centers for Disease Control and Prevention (CDC) is based on a study
that detected ZIKV RNA in semen for as long as 188 days after symptom onset [71]. The guidance
states that women and men who reside in areas of transmission and experience symptoms of Zika
disease should be tested for ZIKV infection. Men with results that indicate recent ZIKV or another
unspecified flavivirus infection should wait at least six months from symptom onset before attempting
conception with their partner, while women should wait at least eight weeks from symptom onset
before attempting to conceive [111].
In 2016, a protocol was published on reproduction rights and pre-natal, delivery, and puerperal
care in response to microcephaly and other CNS disorders [112], but the report did not mention
abortion, which is illegal in Brazil. The number of live births dropped by 15% between September
and December 2016 in Rio de Janeiro compared to the previous year [113]. Possible reasons include
delayed pregnancy, ZIKV increasing the risk of miscarriage and fetal death, voluntary abortion, or
pregnancy interruption [114]. However, many women in Brazil have unwanted pregnancies and are at
risk of unsafe abortion, which needs to be urgently addressed by the public health system [115–118].
6. Social and Economic Impact
Congenital Zika Syndrome (CZS), including severe microcephaly and a range of other birth
defects, has wide-ranging impacts for the child, the family, and society as a whole. Children with
CZS are likely to have a broad range of intellectual, physical, and sensory impairments, which
will be life-long. CZS is new, but childhood disability is not, and its impacts are well-established.
Extensive evidence shows that children with disabilities face a range of exclusions and difficulties [119].
For instance, childhood disability is strongly linked to poverty [120], malnutrition [121], vulnerability
to violence [122], poor health [123], and exclusion from schools [123]. These difficulties are likely to
continue into the future, as adults with disabilities are less likely to be employed, and more likely to
face poverty and wide-ranging social exclusion [119,120].
Children with CZS are disproportionately born to women and girls of low socio-economic
status, who are usually the main caregivers [115]. The negative impacts of being a carer are
now well-recognised [124], including vulnerability to anxiety and depression [125] and deepening
poverty [126]. The impact of CZS extends beyond the mother alone, affecting the whole family.
The arrival of a child with disabilities into a family can often be a trigger for fathers to abandon the
family. It may also negatively impact siblings, as less care and attention can be dedicated to them [115].
Looking beyond the family, there are wider societal impacts of CZS. The epidemic may have
affected child-bearing decisions of young adults, as well as cause concern among pregnant women.
Health professionals may face the strain of having to deal with a new condition, the trajectory of which
is unknown, and for which services are not widely available. The impact may be experienced on a
broader national level, as the health system comes under pressure and as the economic consequences
for affected families coalesce at the societal level. Overall, these factors may create further social and
economic concerns within Brazil, which is a country currently experiencing widespread political and
economic problems.
Solutions should be targeted to address the full range of impacts of CZS. Currently, most efforts
are being made to meet the medical needs of the affected children. A large focus is on the children
with microcephaly, while those less severely affected may experience gaps in their treatments, as
their diagnosis is delayed or they are not prioritised for services. So far, no follow-up of otherwise
healthy children with postnatal ZIKV infection or exposure has been made. Therefore, developmental
complications should be tracked in all potentially exposed children of the “Zika generation” [111,127,128].
Financial support grants have been made available by the government and should be given to most
poor families of children with disabilities, yet those with microcephaly appear to be prioritised while
others with less severe disabilities may be missing out [115], despite the high cost of treatment [126].
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In different parts of Brazil, some support programmes have been implemented, often established by
parents of children with CZS or else by childhood disability programmes. However, these programmes
rarely address the comprehensive needs of families and coverage is patchy. Therefore, there is likely to
be a large unmet need for psychosocial support. Healthcare professionals and family members may
also need further training in how to address the medical and broader need of these children. In the
longer-term, the children will need support to be included in education, employment, and society in
general, in fulfilment of their fundamental rights [129].
7. Knowledge Gaps
This article highlights some of the important scientific advances that have been made since the
emergence of ZIKV in Brazil. However, some gaps in our knowledge of the epidemiology, clinical
evolution, virology, and biology of ZIKV infections remain, including potential domestic and wild
animal reservoirs, amplification hosts, vector capacity of various species, and alternative non-vector
transmission routes (see Figure 5). Unresolved areas of research include: the factors which led to its
explosive emergence; the impact of previous flavivirus infection on the severity of ZIKV infections;
the duration of ZIKV infection immunity; and the level of background immunity required to prevent
emergence or re-circulation of ZIKV in the future.
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Figure 5. Summary of known epidemiological features of ZIKV. Unresolved questions are highlighted
in blue. R0 is the basic reproduction number (the expected number of secondary cases produced by a
single infection in a completely susceptible population).
Substantial evidence now exists on the association between materno-fetal transmission of ZIKV
and congenital CNS malformations. However, several important issues remain unresolved, including:
the transmission rate from infected pregnant women to fetuses; the frequency of infected fetuses
that will develop malformations; and the long-term outcome of infected neonates without detectable
abnormalities at birth. It is still not known if apparently unaffected children whose mothers had ZIKV
in pregnancy will develop normally or develop complications that will only become evident in years
to come.
8. Conclusions
The ZIKV epidemic in Brazil has ended for the time being, and the disease and associated
complications are no longer considered a public health emergency of international concern [130].
However, the outbreak will have long-lasting social and economic impacts, especially for the families
impacted by CZS. The Brazilian Ministry of Health has pledged to maintain actions to confront the
Aedes mosquito and guarantee access to health services for the affected populations [131]. However, the
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national response to the Zika crisis has largely focused on household-level mosquito elimination efforts,
such as cleaning water storage containers, eliminating standing water, and spraying. These efforts are
often futile without addressing systemic problems with public infrastructure, such as limited access
to piped water and poor sanitation [126]. Such conditions provide ideal mosquito habitats, which
exacerbated the recent ZIKV outbreak, as well as outbreaks of other arboviruses in Brazil [115].
Computational models can help understand the role of multiple ZIKV transmission risk factors
at different spatial and temporal scales, such as climate, human mobility, socio-economic status,
asymptomatic infections, and background immunity. They have the potential to assist decision-makers
in understanding where ZIKV will spread next and when the next ZIKV epidemic might occur.
However, effective ZIKV modelling initiatives depend upon flexible and open-access surveillance
systems that are capable of detecting new health threats and improved laboratory diagnostic tools.
A continued and intensified international and interdisciplinary response is needed to improve our
ability to anticipate, control, and mitigate the risk of ZIKV, other reemerging arboviruses, and new
public health threats yet to emerge.
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